Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

eim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in so
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... clinicians and researchers to advisory roles. The panel ... Relmada,s development programs and efforts to advance the ... chronic pain. They bring expertise in a range ...
(Date:3/5/2015)... 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss year-end 2014 financial ... programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation ... TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery ... 2015. To participate in the call, interested parties ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
... - Results suggest pirfenidone may provide meaningful clinical benefit ... efficacy and safety reported -- Conference Call and Webcast ... DIEGO, May 19 InterMune, Inc. (Nasdaq: ... 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic ...
... that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... placebo in patients with Bipolar I Disorder. Results of ... medical meeting. Bipolar Disorder is a brain disorder ... and ability to function. It is often characterized by ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:3/5/2015)... (PRWEB) March 05, 2015 Central Nebraska ... their practice including the brand’s new logo and optimized ... showcase the practice’s modern approach to expert diagnostic imaging, ... mobile-optimized and be built to be a resource for ... community. With automated forms, communication and referral functionality, video ...
(Date:3/5/2015)... Angeles, CA (PRWEB) March 05, 2015 ... article titled “Butt Augmentation, Labiaplasty on the Rise, Plastic ... reported by the American Society for Aesthetic Plastic ... Surgeons . Both groups reported a year-over-year doubling of ... of the physicians quoted in the article, this increase ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
(Date:3/5/2015)... Portland, Ore. (PRWEB) March 05, 2015 ... health sciences university founded in 1904, has launched ... behaviors and positive lifestyle changes. The Northwest Center ... educate health professionals, support community outreach, and conduct ... promotion, functional medicine, diet and nutrition. The center ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Dr. Jonathan ... ( http://www.orthopedicsurgeonnyc.com ) has been named by Castle ... York Metro area. Dr. Glashow has been selected by ... guide to the top specialty care doctors in the ... prestigious Castle Connolly program, which carefully screens and selects ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... M.D., a community-based,oncologist in Billings, Montana, has been elected ... group for cancer patients and,professionals. , ... lead COA for the next year," said Dr.,Cobb, who ... in Billings, Montana. "Community cancer care faces severe challenges,and ...
... 13% of people over 20 now have the condition, while ... News) -- The most recent analysis of data on diabetes ... adults aged 20 and older have the condition, 40 percent ... proportion of diagnosed patients than noted in a previous study, ...
... desk to prevent obesity: heart health. , ... Phoenix, ... President to proclaim February as "American Heart Month". Typically this is ... Association and when most Americans are reminded about the causes of ...
... VoIP Fax Server Garners Another Industry Award , ... ... leading provider of reliable VoIP fax server solutions for SMB, Enterprise ... fax server has been named a 2008 "Product of the ...
... Independent Living Systems, LLC (ILS), a,management services company ... and other special care needs, announced the appointment of,The ... long-term,care. In this role, Carbonell will lead the strategic ... and commitment to servicing the,growing Florida aging community. , ...
... says waste, inefficiencies need to be cut out of ... News) -- Unless health-care reform becomes a reality, most ... will double by 2016, a new report claims. , ... jump from $11,381 to $24,291 in the next seven ...
Cached Medicine News:Health News:Dr. Patrick Cobb Named President of Community Oncology Alliance 2Health News:Diabetes Keeps Rising Among U.S. Adults 2Health News:Diabetes Keeps Rising Among U.S. Adults 3Health News:Celebrate American Heart Month with a Treadmill Desk 2Health News:Celebrate American Heart Month with a Treadmill Desk 3Health News:FaxBack's Net SatisFAXtion Named a 2008 "Product of the Year" by TMC's Internet Telephony Magazine 2Health News:FaxBack's Net SatisFAXtion Named a 2008 "Product of the Year" by TMC's Internet Telephony Magazine 3Health News:Former Assistant Secretary for Aging, The Honorable Josefina G. Carbonell, Appointed Senior Vice President at Independent Living Systems 2Health News:Skyocketing Health-Care Costs Could Double Premiums for Many Americans 2Health News:Skyocketing Health-Care Costs Could Double Premiums for Many Americans 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: